Abstract: The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.
Abstract: There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50 mg/kg, and (b) a metallodrug at a clinically-acceptable dosage.
Type:
Grant
Filed:
March 23, 2018
Date of Patent:
July 20, 2021
Assignee:
ISTITUTO SUPERIORE DI SANITÀ
Inventors:
Iart Luca Shytaj, Shailendra Pratap Singh Rathore, Francesco Procopio, Andrea Savarino
Abstract: The present application relates to the use of bacterial CNF (Cytotoxic Necrotizing Factor) and/or DNT (dermonecrotic toxin) as active ingredients or active ingredient for the prevention and/or the treatment of malaria caused by Plasmodium falciparum, pharmaceutical compositions comprising said active ingredient(s) for said use and a method of prevention and/or treatment of malaria, comprising the administration of bacterial CNF (Cytotoxic Necrotizing Factor) and/or DNT (dermonecrotic toxin) or of a composition comprising it/them to a patient in need thereof.
Type:
Application
Filed:
July 27, 2017
Publication date:
April 22, 2021
Applicant:
ISTITUTO SUPERIORE DI SANITA
Inventors:
Carla FIORENTINI, Francesco SILVESTRINI, Stefano LOIZZO, Valeria MESSINA, Sara TRAVAGLIONE, Pietro ALANO
Abstract: A method can determine Attention-Deficit Hyperactivity Disorder (ADHD) and/or evaluate the prognosis and/or determine the effectiveness of a therapy against ADHD. The method is based on measuring the methylation levels of CpG dinucleotides and/or CpG islands in a genomic region of the SLC6A3 gene (solute carrier family 6 member 3), preferably in the 5? UTR.
Type:
Application
Filed:
December 21, 2017
Publication date:
June 11, 2020
Applicants:
Istituto Superiore di Sanita', Universita' degli Studi di Teramo, Universita' degli Studi di Roma "La Sapienza"
Inventors:
Giovanni LAVIOLA, Walter ADRIANI, Esterina PASCALE, Claudio D'ADDARIO
Abstract: There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50 mg/kg, and (b) a metallodrug at a clinically-acceptable dosage.
Type:
Application
Filed:
March 23, 2018
Publication date:
January 23, 2020
Applicant:
ISTITUTO SUPERIORE DI SANITÀ
Inventors:
Iart Luca Shytaj, Shailendra Pratap Singh Rathore, Francesco Procopio, Andrea Savarino
Abstract: The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies, said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses are the following compounds: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof.
Type:
Grant
Filed:
December 23, 2002
Date of Patent:
December 17, 2019
Assignee:
ISTITUTO SUPERIORE DI SANITA
Inventors:
Corrado Spadafora, Patriźia Ĺavia, Elisabetta Mattei, Gugliemo Palombini, Rodolfo Nello Lorenzini, Clara Nervi
Abstract: Complexes comprising HIV Tat and the V3 loop from gp120 Env provide novel epitopes and are immunogenic to prevent or inhibit infection by HIV.
Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
August 15, 2017
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Istituto Superiore di Sanita
Inventors:
Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
Abstract: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.
Type:
Grant
Filed:
March 19, 2014
Date of Patent:
April 4, 2017
Assignees:
Istituto Superiore di Sanita, NovaDigm Therapeutics, Inc.
Inventors:
Rinaldo Zurbriggen, Flavia De Bernardis, Antonio Cassone, Silvia Rasi
Abstract: Tat protein produced in bulk culture is inactive when induced at conventional optical densities but can be obtained in biologically active form when induced during the logarithmic growth phase.
Type:
Grant
Filed:
February 6, 2009
Date of Patent:
August 30, 2016
Assignees:
ISTITUTO SUPERIORE DI SANITA, UNIVERSITA DEGLI STUDI DI URBINO
Abstract: Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof.
Abstract: Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof.
Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.
Type:
Grant
Filed:
December 16, 2014
Date of Patent:
December 22, 2015
Assignees:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di Sanita
Inventors:
Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.
Type:
Grant
Filed:
November 17, 2005
Date of Patent:
January 6, 2015
Assignees:
The Government of The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di Sanita
Inventors:
Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
Abstract: The present invention concerns peptides having protective effect towards inflammatory activity of a-gliadin 31-43 peptide in celiac disease and therefore can be used for preventive and therapeutic purpose by administration thereof to subjects at high risk to develop celiac disease and/or celiac subjects just before a gluten containing meal to be ingested.
Type:
Application
Filed:
September 18, 2012
Publication date:
August 14, 2014
Applicants:
Istituto Superiore Di Sanita, CRA-Sonsiglio per La Ricerca E LA
Inventors:
Marco Silano, Luigi Cattivelli, Pasquale De Vita, Luigi Maiuri, Donatella Bianca Maria Ficco
Abstract: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.
Type:
Grant
Filed:
October 29, 2009
Date of Patent:
July 22, 2014
Assignee:
Istituto Superiore di Sanita
Inventors:
Andrea Savarino, Antonello Mai, Anna Teresa Palamara, Enrico Garaci
Abstract: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.
Type:
Application
Filed:
March 19, 2014
Publication date:
July 10, 2014
Applicants:
Istituto Superiore Di Sanita, Pevion Biotech Ltd.
Inventors:
Rinaldo Zurbriggen, Flavia De Bernardis, Antonio Cassone, Silvia Rasi
Abstract: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.
Type:
Grant
Filed:
September 19, 2008
Date of Patent:
May 6, 2014
Assignees:
Pevion Biotech, AG, Istituto Superiore di Sanita
Inventors:
Rinaldo Zurbriggen, Flavia de Bernardis, Antonio Cassone, Silvia Rasi
Abstract: The present invention refers to 3-aza-bicyclo [3.2.1] octane derivatives of general formula (I) their preparation, use and pharmaceutical compositions useful in the treatment of pathologies associated with microbial pathogens expressing aspartylprotease activity.
Type:
Grant
Filed:
November 24, 2009
Date of Patent:
May 21, 2013
Assignees:
Istituto Superiore di Sanita', Universita' Degli Studi di Firenze
Inventors:
Antonio Cassone, Flavia De Bernardis, Enrico Garaci, Andrea Trabocchi, Antonio Guarna